CoChat

Hereditary tyrosinemia type I: Self-induced correction of the fumarylacetoacetase defect

Open access
Kvittingen, E A, Rootwelt, H, Brandtzaeg, P, Bergan, A, Berger, R · 1993 · Journal of Clinical Investigation

The DOI matches its Crossref record; 17 of the 20 references it cites were found in a registry or an index; none of the 9 sources its claims cite is checked for support yet.

Abstract

Two Norwegian patients with chronic tyrosinemia type I showed > 50% residual fumarylacetoacetase activity in liver samples obtained during liver transplantation. The enzyme characteristics of both patients were comparable with those of a normal control. Immunohistochemistry on liver sections from these patients and from three other Norwegian tyrosinemia patients revealed a mosaicism of fumarylacetoacetase immunoreactivity corresponding completely or partly to some of the regenerating nodules. This appearance of enzyme protein is presumably induced by the disease process. The mechanism involved remains unclear and could be caused by a genetic alteration, regained translation of messenger RNA, or to enhanced stability of an abnormal enzyme.

Overview

CoChat Summary

## TL;DR

This study reports unexpected residual fumarylacetoacetase (FAH) activity and mosaic FAH immunoreactivity in liver tissue from patients with hereditary tyrosinemia type I, suggesting self-induced correction of the enzyme defect in some hepatocyte clones. The authors argue that this mosaicism could make liver-biopsy-based diagnosis misleading in chronic cases.

## Key findings

  • In two Norwegian patients with chronic tyrosinemia type I, frozen liver samples taken at transplantation showed substantial FAH activity: patient 1 had 6–32 U/g protein and patient 2 had 26 U/g protein, compared with 33–66 U/g protein in controls.
  • Immunohistochemistry showed a mosaic pattern of FAH staining in regenerating nodules; in patient 2, one section showed FAH immunoreactivity in only two regenerating nodules, while another section from the same patient showed all nodules positive.
  • Similar mosaic FAH staining was seen in the other studied tyrosinemia patients, including patient 4, and the authors state mosaicism was observed in patients 1, 3, and 5 as well.
  • The FAH enzyme from patients 1 and 2 had Km, Vmax, pH optimum, inhibition pattern toward metal ions, and freeze/thaw stability comparable with a normal control, supporting the idea that the reexpressed enzyme was functionally normal.

## Methods

  • The study examined five Norwegian tyrosinemia type I patients diagnosed at 1–6 years of age by low FAH activity in fibroblasts and/or lymphocytes plus elevated urinary succinylacetone.
  • Liver tissue collected at transplantation was analyzed by FAH activity assays, Western blotting, subcellular fractionation (patient 2), and immunohistochemistry using the APAAP method on formalin-fixed paraffin-embedded sections.
  • The authors compared enzyme kinetics and inhibitor sensitivity in patients 1 and 2 with a normal control, and also examined liver sections from normal controls and patients with cirrhosis from other causes.

## Limitations

  • The paper does not identify the mechanism of correction; it explicitly says the mechanism remains unclear and could involve a genetic alteration, regained translation of mRNA, or enhanced stability of an abnormal enzyme.
  • The findings are based on a small sample of five patients, with detailed biochemical characterization concentrated in two patients.
  • Evident from the text: the study is observational and cannot determine causality for the mosaicism or prove which proposed mechanism is correct.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1172/jci116393

Cites

17 of 17 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Image 1
From the PDF
Figure 2 Immunohistochemical staining (APAAP) of two liver sections from patient 2. The overviews show one section (A) with fumarylacetoacetase immunoreactivity in only two regenerating aso e t ee sade oe d os pe e ae ( sts e un s e s e u e nodsod a o a n a ots as o ( otn n t nnt seo od sion (n os s sen sive
Figure 2 Immunohistochemical staining (APAAP) of two liver sections from patient 2. The overviews show one section (A) with fumarylacetoacetase immunoreactivity in only two regenerating aso e t ee sade oe d os pe e ae ( sts e un s e s e u e nodsod a o a n a ots as o ( otn n t nnt seo od sion (n os s sen siveFrom the PDF
Image 3
From the PDF
Image 4
From the PDF

Verification

Claims the paper makes

0 Valid · 1 Not valid · 6 Not checked · 18 Own results and interpretations

10 more claims

Create a free account to see all 25 claims and every source verdict.

See all claims — free account
  • Borderline: one of the tests for a substantial claim is unclear. 1
  • Probably not a substantial claim. 4
  • It may state two separate claims as one. 6

Create a free account to see these claims.

Citations

Cites

Research works printed but not linked: 1

  1. [1]1. Goldsmith, L. A., and C. Laberge. 1989. Tyrosinemia and related disorders. In The Metabolic Basis of Inherited Disease. C. R. Scriver, A. L. Beaudet, W. -S. Sly, and D. Valle, editors. McGraw-Hill Inc., New York 547–562.

Cited by

See all 102

Metadata

Authors
Kvittingen, E. A., Rootwelt, H., Brandtzaeg, P., Bergan, A., & Berger, R.
Affiliations
  • University of Oslo (NO)
  • Oslo University Hospital (NO)
Venue
Journal of Clinical Investigation
Published
1993-04-01
Volume
91
Issue
4
Pages
1816-1821
ISSN
0021-9738 (ISSN-L)
OpenAlex
W2162704354
Cited by
102
References
20
Citations by year
2025: 1 · 2023: 1 · 2022: 1 · 2021: 4 · 2020: 1 · 2019: 2 · 2018: 3 · 2017: 5 · 2016: 1 · 2015: 2 · 2014: 1 · 2013: 4 · 2012: 3
FWCI
2.95
Type
journal article
Language
en
Open access
Locations
  • Journal of Clinical Investigation (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Clinical Biochemistry › Metabolism and Genetic Disorders
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Amino Acid Enzymes and Metabolism
  • Health Sciences › Medicine › Genetics (clinical) › Lysosomal Storage Disorders Research
Keywords
tyrosinemia type I, liver transplantation, residual enzyme activity, enzyme induction, mosaicism, immunohistochemistry, liver regeneration, enzyme stability, mRNA translation
MeSH terms
Amino Acid Metabolism, Inborn Errors, Child, Child, Preschool, Family Health, Fibroblasts, Humans, Hydrolases, Immunohistochemistry, Infant, Liver, Norway, Subcellular Fractions, Tyrosine, Blotting, Western

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.